Member Info for Chelsea11

Ok we disagree. It’s allowed. Cool.

Hi Konar - apols for the delay in responding to you.

I would argue that updates this year including 1st iSCIB+ patient dosed, Modi RCC patients trial expansion and more recently, the iSCIB+ Clinical Advisory Meeting containing updated numbers of patients dosed, are all Clinical Updates.

Konar - here is what you stated originally ie. a quote of your own words.

“ We haven't had a SCIB1 update since (i think) November 2023 and Moditope since (again - i think) February 2023.”

Factually incorrect and the RNS’s since 2023 evidence that.

Konar - there have been updates on both SCOPE and Modi since 2023.

Curiously, no mention of CICON24 running from Sept 8th-11th, given 3 posters presented at that conference last year.

http://www.cancerimmunotherapyconference.org

Maybe as simple as not being able to be in two places at the same time. Positive step-change in the last 12 months re showcasing the significant recent progress and benefits of the Scancell armoury.

Cleaner, your 10:50 today.

Thanks for your note re Foram Dave papers - appreciated. Important that investors are not confused by posts.

Re Chilltimes “the full readout on iSCIB+ is early 2025”. I’d just caution that by adding the context that it will relate to the cohort of 43 patients only (so only “full” in that sense) and also that early 2025 could be as late as March, given the update of timeline we received from the company, was Q1.

We all hope of course that it comes much sooner than that and as I have mentioned previously, it isn’t impossible it could be released alongside SCIB1 data due earlier, due to faster recruitment for iSCIB+.

Not long to wait regardless.

Cleaner - no idea what you’re on about.

You posted a link yesterday to a paper Foram Dave had contributed to and you received a response to say it had nothing to do with Scancell. That post is still there if you care to review it.

The content of that and the link you’ve just referred to, are completely different 😂

Wanna explain?

I’m not sure what keeping it under wraps achieves tbh. Surely, publishing it promotes by the trajectory of the trial and the company itself, thereby putting us more prominently in the shop window. Conversely, not publishing it might seen as a negative.

Q1 2025 is still some way off, especially the latter end and if it slips into Q2. I’d hope we see something on iSCIB1+ progress before that.

Equally, if not more important, to have a contextual explanation in harness with the article, to avoid any investor misinterpretation. Thanks Berm.

Reminder of the upcoming, prestigious global conference, beginning in just over 1 week 08/09.

http://www.cancerimmunotherapyconference.org/

3 Posters in 2023 can be seen on the Scancell website. I’d hope to see a related RNS this year.

Surely all that needs to be said is…………

You wouldn’t want to be out of this over a Bank Holiday Weekend 🤪

HAGW

Agree with your far more general summary of those products Ray and the point you make of Lindy’s awareness BUT the convo related very specifically to Mabsolve and the posts Cleaner made. On those, yet again, no context, no explanation and frankly, nothing new at all that a Scancell investor didn’t know from an RNS 2 years ago. It’s just another random blat from an internet search engine. Others here must surely see that and agree.

You’re absolutely right Cleaner - I don’t understand your posts. What I do understand though, from your own responses, is that you clearly don’t understand them either.

Ancient history. What does it mean for Scancell investor today, that we didn’t already know from the Scancell RNS two years ago?

Yes Cleaner, Scancell in-licenced Fc silencing technology from Oxford-based mAbsolve. As has been pointed out, we knew that 2 years ago.

So rather than just random posting the Wiley Online Library link, can you articulate your point and the significance of it ie. a contextual explanation that shows you understand what you are posting and it isn’t just another copy & paste blat from an internet search.

A fair, reasonable and polite challenge?

Investors choice I guess. Go with the if, buts & maybes statements. Or alternatively, the officially published figures.

BOJO - I posted on here that I sold some recently I was holding outside of an ISA wrapper, whilst retaining a larger tranche inside an ISA. Having made a profit on the sale, it de-risks somewhat those I continue to hold.

I’m obviously not righteous then 😂

Ray - surely both are, or would be, a catalyst for SP movement?

Not looking likely to me, that we’ll see 20p this week. However, if we finish the week where we started it around 18.5p ish, I’d suggest that after the steep recent rise, that’s not a bad result at all. Next week could easily be the next leg of a tick up based on the buying we’ve seen. Who knows, might even be some weekend media coverage.

HAGW.

Yes there are many companies struggling and for historic reasons. But to say there is a recession, when news as recent as today states the opposite, is clearly misleading and incorrect.